# A Study of Tirzepatide (LY3298176) in Japanese Participants With Type 2 Diabetes

> **NCT03322631** · PHASE1 · COMPLETED · sponsor: **Eli Lilly and Company** · enrollment: 48 (actual)

## Conditions studied

- Type 2 Diabetes Mellitus

## Interventions

- **DRUG:** Tirzepatide
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT03322631
- **Lead sponsor:** Eli Lilly and Company
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2017-11-15
- **Primary completion:** 2018-05-29
- **Final completion:** 2018-11-28
- **Target enrollment:** 48 (ACTUAL)
- **Last updated:** 2023-03-23


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03322631

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03322631, "A Study of Tirzepatide (LY3298176) in Japanese Participants With Type 2 Diabetes". Retrieved via AI Analytics 2026-06-12 from https://api.ai-analytics.org/clinical/NCT03322631. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*